North America Spinal Cord Injury Treatment Market
市场规模（十亿美元）
CAGR :
% 
USD
2.76 Billion
USD
4.10 Billion
2024
2032
 Forecast Period |
2025 –2032 |
 Market Size (Base Year) |
USD 2.76 Billion |
 Market Size (Forecast Year) |
USD 4.10 Billion |
 CAGR |
% |
| Major Markets Players |
|
北美脊髓損傷治療市場，按類型（非手術治療和手術治療）、損傷類型（完全性脊髓損傷和部分性脊髓損傷）、損傷程度（頸段脊髓損傷、胸段脊髓損傷、腰段脊髓損傷和骶段脊髓損傷）、性別（男性和女性）、最終用戶（醫院、創傷中心、專科診所、診所、門診和研究中心等）
北美脊髓損傷治療市場分析
根據《國際衛生政策與管理期刊》 2021 年 5 月發表的一篇文章，合作方式在脊髓損傷 (SCI) 健康研究領域越來越受歡迎，為探索和學習 SCI 研究合作冠軍的成功創造了機會。北美脊髓損傷治療市場日益增長的合作和不斷擴大的夥伴關係對於推動創新、推動研究和改善患者護理至關重要。透過結合不同領域的專業知識，這些合作促進了新療法的開發、增強了復健技術並改進了醫療設備。
北美脊髓損傷治療市場規模
北美脊髓損傷治療市場預計將從 2024 年的 27.6 億美元增至 2032 年的 41 億美元，在 2025 年至 2032 年的預測期內以 5.1% 的複合年增長率增長。除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。
北美脊髓損傷治療市場趨勢
“加強合作，拓展夥伴關係”
在不斷發展的脊髓損傷 (SCI) 研究領域，一個顯著的趨勢是學術機構、研究組織、製藥公司和醫療器材製造商之間的合作日益增加。這些聯盟促進了專業知識、資源和資金的共享，以應對 SCI 固有的挑戰——例如有限的再生能力和治療的複雜性。透過整合各方優勢，這些合作關係正在加速創新療法的開發，包括幹細胞治療、神經假體和基因療法。此外，產業利害關係人正在聯手加強復健計畫、改善行動輔助設備並改善診斷工具。一個新興趨勢是臨床數據的集體共享，這加深了我們對 SCI 病理生理學的理解，並有助於制定個人化的治療策略。此外，北美醫療保健提供者和政策制定者之間的合作正在推動改革，以改善獲得尖端治療的機會並確保其可負擔性。總體而言，這些合作趨勢不僅提高了護理標準，而且推動了全球治療脊髓損傷的努力，最終改變了患者的生活。
報告範圍和北美脊髓損傷治療市場細分
|
屬性 |
北美脊髓損傷治療市場洞察 |
|
涵蓋的領域 |
|
|
覆蓋區域 |
美國、加拿大、墨西哥、德國、英國、法國、俄羅斯、義大利、西班牙、土耳其、波蘭、荷蘭、瑞士、挪威、奧地利、愛爾蘭、歐洲其他地區、中國、日本、印度、澳洲、韓國、新加坡、泰國、菲律賓、馬來西亞、印尼、越南、台灣、亞太其他地區、巴西、阿根廷、智利、秘魯、其他地區、沙烏地阿拉伯、阿聯酋、美國、南非、其他地區、以色列、 |
|
主要市場參與者 |
諾華公司（瑞士）、輝瑞公司（美國）、美敦力公司（愛爾蘭）、Zimmer Biomet 公司（美國）、雅培公司（美國）、Amneal Pharmaceuticals LLC（美國）、賽諾菲公司（法國）、Axonis Therapeutics 公司（美國）、Zydus Group 公司（印度）、Line Industries Therapcetical（美國）、Sunstical 公司（印度）、Line Industries）公司（美國）、Dr. Reddy's Laboratories Ltd.（印度）、Teva Pharmaceuticals US, Inc.（以色列）、Niksan Pharmaceuticals（印度）、Covis Pharma GmbH（瑞士）、印度脊髓損傷中心（印度）、Jubilant Cadista Pharmaceuticals Inc.（美國）、強生公司（美國）（Necare）、加拿大） Pharma（美國）、波士頓科學公司（美國）、Vasudha Pharma（印度）、Enomark（印度）、Glenmark Pharmaceuticals US Inc.（美國）、Inova Pharmaceuticals（澳洲）、Globus Medical（美國）、Zimvie Inc.（美國）和 Bioaxone（加拿大） |
|
市場機會 |
|
|
加值資料資訊集 |
除了對市場價值、成長率、細分、地理覆蓋範圍和主要參與者等市場情景的洞察之外，Data Bridge Market Research 策劃的市場報告還包括進出口分析、生產能力概覽、生產消費分析、價格趨勢分析、氣候變遷情景、供應鏈分析、價值鏈分析、原材料/消耗品概覽、供應商選擇標準、PESTLE 分析、波特分析和監管框架。 |
北美脊髓損傷治療市場定義
脊髓治療涉及各種醫療方法來治療影響脊髓的損傷、疾病或障礙。根據病情的嚴重程度和情況，治療可能包括使用止痛藥、抗發炎藥或肌肉鬆弛劑等藥物來減輕症狀。為了穩定和修復，可能需要減壓或脊椎融合等手術幹預。物理治療有助於恢復活動能力和增強肌肉，而復健治療則支持日常活動和獨立性。輪椅和支架等輔助設備有助於運動，而幹細胞療法等新興治療方法則具有潛在的再生益處。心理支持和替代療法（包括針灸和水療法）也可以促進康復。多學科方法和早期介入對於獲得更好的結果至關重要。
全球脊髓損傷治療市場動態
驅動程式
加強合作，擴大夥伴關係
隨著 SCI 研究的不斷發展，學術機構、研究組織、製藥公司和醫療器材製造商之間的合作變得越來越重要。這些合作關係可以匯集專業知識、資源和資金，以克服與脊髓損傷相關的重大挑戰，包括有限的再生潛力和治療的複雜性。透過合作努力，幹細胞治療、神經修復和基因治療等創新療法的開發得到了加速。此外，產業參與者正在合作創建更有效的復健計劃，改善行動輔助器等醫療設備，並建立更好的診斷工具。擴大合作夥伴關係還提供了共享臨床數據的平台，這對於增強對 SCI 病理生理學的理解和優化個人化治療策略至關重要。此外，全球醫療保健提供者和政策制定者之間的合作有助於推動醫療改革，改善獲得尖端治療的機會，並確保 SCI 治療的可負擔性。最終，這些不斷發展的合作夥伴關係不僅提高了護理質量，而且還為全球尋找治療脊髓損傷的方法做出了貢獻，推動了創新並改善了全球脊髓損傷患者的生活。
例如，
- 2021 年 5 月，根據《國際衛生政策與管理期刊》發表的一篇文章，合作模式在脊髓損傷 (SCI) 健康研究領域越來越受歡迎，為探索和學習 SCI 研究合作倡導者的成功經驗創造了機會
- 2023 年 5 月，根據 TechTarget Network 發表的一篇文章，里夫基金會和阿爾伯塔大學的合作旨在促進脊髓損傷研究中的開放資料共享，以促進價值、共享知識和資料透明度。阿爾伯塔大學和里夫基金會啟動了一項為期三年的聯合項目，旨在透過脊髓損傷開放資料共享中心 (ODC-SCI) 促進開放資料共享
全球脊髓損傷治療市場中日益增長的合作和不斷擴大的夥伴關係對於推動創新、推動研究和改善患者護理至關重要。透過結合不同領域的專業知識，這些合作促進了新療法的開發、增強了復健技術並改進了醫療設備。因此，脊髓損傷患者將受益於更有效、個人化的治療和更好的治療效果。透過對合作關係的持續投資，市場有望在脊髓損傷的治療和潛在治癒方面取得重大進展，最終改善全球數百萬人的生活品質。
治療方法的技術進步
幹細胞療法、神經假體和先進的神經刺激技術等創新正在顯著改善脊髓損傷患者的復健前景。機器人外骨骼和人工智慧的開發可用於制定個人化治療計劃，從而提高康復效果。此外，脊髓再生生物材料和CRISPR等基因編輯技術的突破，為恢復失去的功能帶來了新的希望。隨著越來越多的患者尋求先進的解決方案來改善生活質量，這些尖端治療方法不僅提高了治療效果，而且還擴大了市場。
例如，
- 2023年10月，根據NCBI發表的一篇文章，SCI治療的技術進步，例如水凝膠等柔性生物材料的開發，解決了組織修復的挑戰。這些材料透過適應病變形狀、防止纖維化和促進軸突生長來支持脊髓再生
- 2021年7月，根據NCBI發表的一篇文章，脊髓損傷治療的技術進步，例如硬膜外電刺激（EES），在臨床前和臨床研究中都顯示出了良好的效果。 EES 增強了脊髓損傷後的感覺和運動功能，凸顯了其改善復健結果的潛力。這項創新凸顯了電刺激在脊髓損傷復健中日益重要的作用
技術進步正在改變脊髓損傷治療的格局，為患者帶來新的希望，並顯著改善復原結果。幹細胞治療、神經修復、神經刺激和人工智慧驅動的個人化治療方面的創新正在增強康復前景。生物材料和基因編輯方面的突破進一步突破了脊髓再生的界限，恢復了失去的功能並提高了生活品質。隨著這些尖端治療方法的不斷發展，SCI 治療市場將會成長，為有需要的人提供更先進、更有效的解決方案。
機會
老年人口不斷增加
隨著年齡的增長，人們的骨密度、肌肉力量和平衡能力往往會下降，這使得他們更容易跌倒——這是該族群脊髓損傷的主要原因。這種人口結構的變化意味著需要專門治療和復健服務的患者群體不斷增長。需求不僅在於受傷後的立即護理，還在於脊髓損傷相關併發症（如疼痛、痙攣和壓瘡）的長期管理，這些併發症通常需要持續的醫療護理。
例如，
- 2024年1月，根據美國人口參考局發表的文章，預計到2050年，美國65歲及以上人口數量將從2022年的5800萬增加到8200萬（增長47%），65歲及以上年齡組佔總人口的比例預計將從17%上升到23%。老年人口的成長會導致脊椎損傷，從而推動需求並擴大脊椎損傷治療市場。
- 2019年10月，根據美國國家醫學圖書館發表的一篇文章，60%的研究確定了功能障礙的等級以及功能困難、日常生活活動和身體能力。這篇評論顯示老年人中腰痛的盛行率很高，且有功能障礙。
此外，老年族群在 SCI 治療中往往面臨獨特的挑戰，需要採取針對性的治療方案和創新的解決方案。老年人可能存在一些先前存在的疾病，這會使治療計劃複雜化，並需要專門的護理策略。這種情況推動了針對特定年齡的治療和輔助設備的研究和開發的需求。此外，重點不僅在於解決脊髓損傷的身體方面，還包括心理健康支持、社會融合和提高老年患者的生活品質。因此，老年人口的增加成為脊髓損傷治療市場成長和多樣化的催化劑，迫使利害關係人進行創新並提供針對老年人需求的全面照護解決方案。
創傷性損傷發生率上升
創傷性損傷，例如機動車事故、跌倒、運動傷害和暴力造成的損傷，為全球脊髓損傷 (SCI) 治療市場帶來了重大機會。隨著這些事件發生頻率的增加，遭受脊髓損傷的人數也在增加，從而擴大了潛在的治療患者群體。這種趨勢在年輕族群中尤其明顯，他們往往更容易參與高風險活動。對有效和先進治療方案的需求，包括緊急護理、手術幹預、復健服務和輔助技術，推動了 SCI 治療市場的成長。醫療器材製造商、製藥公司和醫療保健提供者可以利用這一趨勢，開發和行銷創傷性脊髓損傷患者需求的創新治療方法和服務。
例如，
- 2022年6月，根據美國國家醫學圖書館發表的一篇文章，過去30年來，SCI的發生率和負擔增加。男性和老年人受到的影響比女性和年輕人更大。跌倒和道路傷害是大多數 SCI 的主要原因。
- 2024年4月，根據世界衛生組織發表的一篇文章，全球有超過1,500萬人患有脊髓損傷（SCI）。大多數脊髓損傷病例都是由創傷引起的，包括跌倒、交通事故或暴力。
創傷性損傷發生率的上升推動了全球脊髓損傷治療市場的大幅擴張，為各個醫療保健領域創造了機會。專注於針對該患者群體的特定需求而量身定制的創新有效的解決方案至關重要。持續開發和提供先進的治療方法對於滿足日益增長的需求和改善脊髓損傷患者的治療效果至關重要。
人工智慧與大數據分析的結合
透過利用人工智慧演算法和大量患者數據，研究人員可以識別以前未知的模式和相關性，從而製定更有效的治療策略和個人化護理計劃。人工智慧可以幫助預測治療結果、優化復健計劃並簡化患者護理流程。此外，使用機器學習演算法可以幫助識別高風險患者，實現主動幹預並降低併發症的可能性。這種數據驅動的方法還可以促進更準確的診斷工具和預測模型的開發，最終提高 SCI 患者的護理品質。
例如，
2023年4月，根據美國國家醫學圖書館發表的一篇文章，在急性脊髓損傷護理中，生成式人工智慧可以分析生命徵象、實驗室結果和其他患者數據，以預測壓瘡、泌尿道感染或其他併發症的可能性。這可以幫助臨床醫生儘早幹預，從而改善患者的治療效果並降低醫療成本
2023年4月，根據《歐洲放射學雜誌》發表的一篇文章，脊椎的早期人工智慧應用已在局部病變的評估中表現出顯著的實用性。例如，一些演算法已經能夠檢測出脊髓早期壓縮性脊髓病變化和脫髓鞘病變，而這些病變在正常顯示的 MRI 影像上是無法發現的
透過利用人工智慧驅動的洞察力，製造商可以設計和製造更有效、更適應的輔助技術，以滿足個別患者的獨特需求。此外，使用遠距醫療和遠端監控平台可以提高患者的參與度和依從性，而人工智慧聊天機器人和虛擬助理可以為患者提供全天候支援和指導。透過採用人工智慧和大數據分析，脊髓損傷治療市場的利害關係人可以徹底改變患者護理，提高醫療服務的效率，並推動產業成長。科技與醫療保健的融合可以創造更有效的治療方式、改善患者的治療效果以及更個人化的 SCI 護理方法。
限制/挑戰
脊髓治療的潛在風險、副作用和併發症
目前脊髓損傷的一些治療方案，包括手術介入和藥物治療，具有一系列潛在的副作用、併發症和長期風險。手術對於某些損傷來說是必不可少的，但有時會導致感染、出血或周圍組織損傷，這可能會進一步損害患者的病情。此外，手術還存在神經系統併發症的可能性，例如癱瘓或運動功能喪失。對於藥物治療，噁心、頭暈和對止痛藥的依賴等副作用會使康復過程變得複雜。在更嚴重的情況下，用於控制疼痛或發炎的藥物可能會導致器官損傷或免疫抑制等長期問題。這些風險可能會使許多患者不願意尋求這些治療方案，特別是當他們擔心自己的健康狀況可能惡化或出現新的併發症時。因此，有些患者可能會選擇避免或延遲這些治療，選擇可能尚未經過廣泛臨床試驗的替代療法或非傳統療法。這種不願意採用傳統治療方法的態度最終會影響患者的復原過程，可能會延遲病情改善或降低整體治療效果。此外，對於面臨脊髓損傷終身後果的患者來說，持續的治療風險和併發症的負擔可能會增加身體和情緒上的負擔，使繼續治療的決定變得更具挑戰性。
例如
- 2024年12月，根據NCBI發表的一篇文章，慢性或腫瘤性脊髓損傷可能出現持續性背痛、全身症狀（體重減輕、發燒、厭食）和進行性感覺運動無力等症狀。隨著病灶的擴大，可能會出現運動障礙，包括喪失抓握能力和活動能力。危險因子包括吸菸、先前的癌症治療、結核病暴露、近期手術和免疫抑制。
- 2025年1月，根據NCBI發表的一篇文章，脊髓損傷（SCI）可導致各種併發症，包括肺炎、循環問題、肌肉僵硬、自主神經反射異常、壓瘡、神經性疼痛、膀胱和腸道問題、性功能障礙和憂鬱症。患者需要仔細監測、採取預防措施和專門治療，例如藥物治療、物理治療和情緒支持來應對這些挑戰。
雖然手術和藥物治療對於脊髓損傷的恢復至關重要，但它們也伴隨著巨大的風險，包括感染、神經系統併發症和長期副作用。這些潛在的缺點常常使患者不願追求或完全致力於這些治療，擔心進一步的傷害或生活品質下降。因此，患者可能會轉向替代療法，但這些療法可能並不總是那麼有效。這強調了對更安全、更有效的治療方案的需求，並強調了提供全面護理以平衡潛在風險和復原可能性以更好地支持 SCI 患者的重要性。
對脊髓損傷治療的理解有限
對脊髓損傷 (SCI) 複雜病理生理學的理解有限，嚴重阻礙了有效治療方法的開發，並對全球 SCI 治療市場構成了重大挑戰。 SCI 涉及分子和細胞層面的一系列事件，導致神經元損傷、發炎和神經膠質瘢痕形成，所有這些都會導致功能缺陷。由於缺乏對這些複雜過程的全面了解，很難確定精確的治療目標和設計能夠有效促進神經再生和功能恢復的干預措施。因此，目前的許多治療著重於控制症狀和預防併發症，而不是解決 SCI 的根本原因。
例如，
- 2020年10月，美國國家醫學圖書館發表的一篇文章指出，脊髓損傷的複雜特徵、大量的不一致性以及脊髓損傷後複雜的病理生理後果等異質性因素是導致脊髓損傷治療理解不足和失敗的主要原因
- 2023年2月，牛津大學出版社發表的一篇文章指出，脊髓損傷的病理生理學複雜且多面，因此針對特定方面或過程的個體治療不足以引發脊髓損傷後的神經元再生和功能恢復
這種知識差距也阻礙了個人化治療策略的發展。 SCI 並不是一個統一的病症，每個患者的損傷嚴重程度、神經功能缺損和功能限製程度都不同。如果不徹底了解導致每個患者受傷的具體機制，那麼根據他們的個人需求制定治療計劃就會變得很困難。這會導致治療效果不理想並降低患者滿意度。此外，對 SCI 的了解有限，阻礙了準確的診斷工具和生物標記的開發，從而難以監測治療效果和預測長期結果。克服這項挑戰需要對基礎研究和轉化研究進行大量投資，以解開 SCI 的複雜性並為更有效和更有針對性的治療鋪平道路。
北美脊髓損傷治療市場範圍
市場根據類型、傷害類型、傷害程度、性別、最終用戶和分銷管道進行細分。這些細分市場之間的成長將幫助您分析行業中成長微弱的細分市場，並為用戶提供有價值的市場概覽和市場洞察，幫助他們做出策略決策，確定核心市場應用。
類型
- 非手術治療
- 治療
- 復健治療
- 身體的
- 職能治療或語言治療
- 鞘內巴氯芬療法（IBT）
- 復健治療
- 藥物
- 抗驚厥藥
- 皮質類固醇
- 甲基強的松龍
- 地塞米松
- 抗憂鬱藥
- Ssris（選擇性血清素再攝取抑制劑）
- Snris（血清素和去甲腎上腺素再攝取抑制劑）
- 三環類藥物
- 抗焦慮藥物
- 解痙藥和肌肉鬆弛藥
- 苯二氮平類藥物
- α-2激動劑
- 其他 Gaba 激動劑
- 其他的
- 非類固醇抗發炎藥
- 布洛芬
- 萘普生
- 其他的
- 麻醉性止痛藥
- 抗生素
- β-內醯胺類（青黴素、頭孢菌素）
- 大環內酯類（阿奇黴素、紅黴素）
- 米諾環素（四環素類）
- 氨苯砜
- 其他（氟喹諾酮類、氨基糖苷類等）
- 治療
- 依藥物類型
- 通用的
- 品牌
- 美卓樂
- 利奧雷薩爾
- 抒情詩
- 神經妥樂平
- 贊那福
- 格拉利斯
- 地平線
- 力如太
- 依給藥途徑
- 口服
- 平板電腦
- 膠囊
- 腸外
- 透皮貼劑
- 營運管理
- 減壓手術
- 椎間盤切除術或顯微椎間盤切除術
- 椎板切除術
- 後路顯微椎間盤切除術/顯微減壓術
- 椎間孔切除術
- 脊椎重建手術
- 後頸椎板切除術
- 椎板切開術
- 光碟更換
- 人工頸椎間盤植入術
- 人工椎間盤手術/脊椎關節置換術
- 椎間盤和小關節切除
- 前路頸椎間盤切除術
- 脊椎融合
- 腰椎融合術
- 頸椎融合術
- 六分儀融合
- 內側關節面切除術
- 移除兩個小關節
- 移除一個小關節
- 其他的
- 減壓手術
損傷類型
- 完全性脊髓損傷
- 部分脊髓損傷
受傷程度
- 頸脊髓損傷
- 完全性脊髓損傷
- 部分脊髓損傷
- 胸段脊髓損傷
- 完全性脊髓損傷
- 部分脊髓損傷
- 腰椎脊髓損傷
- 完全性脊髓損傷
- 部分脊髓損傷
- 骶脊髓損傷
- 完全性脊髓損傷
- 部分脊髓損傷
性別
- 男性
- 成人
- 老年
- 孩子們
- 女性
- 成人
- 老年
- 孩子們
最終用戶
- 醫院
- 創傷中心
- 專科診所
- 診所
- 流動和研究中心
- 其他的
分銷管道
- 醫院藥房
- 零售藥局
- 網路藥局
北美脊髓損傷治療市場區域分析
對市場進行分析，並按國家、類型、傷害類型、傷害程度、性別、最終用戶和分銷管道提供市場規模洞察和趨勢，如上所述。
脊髓損傷治療市場涵蓋的國家包括美國、加拿大和墨西哥。
由於美國在醫療保健基礎設施、先進醫學研究和政府支持政策方面投入了大量資金，預計它將主導北美脊髓損傷治療市場。此外，其龐大的人口加上對創新脊髓治療日益增長的需求鞏固了其市場領先地位。
預計美國脊髓損傷治療市場將出現最高的複合年增長率。這一增長得益於積極的醫療保健投資、政府對創新的大力支持以及治療技術的快速進步。此外，不斷擴大的患者群體和對尖端療法不斷增長的需求也對這一加速增長做出了巨大貢獻。
報告的國家部分還提供了影響個別市場因素以及影響市場當前和未來趨勢的國內市場監管變化。下游和上游價值鏈分析、技術趨勢和波特五力分析、案例研究等數據點是用於預測各國市場情景的一些指標。此外，在對國家數據進行預測分析時，還考慮了北美品牌的存在和可用性以及由於來自本地和國內品牌的大量或稀缺的競爭而面臨的挑戰、國內關稅和貿易路線的影響。
北美脊髓損傷治療市場份額
市場競爭格局提供了競爭對手的詳細資訊。詳細資訊包括公司概況、公司財務狀況、收入、市場潛力、研發投資、新市場計劃、北美業務、生產基地和設施、生產能力、公司優勢和劣勢、產品發布、產品寬度和廣度、應用優勢。以上提供的數據點僅與公司對市場的關注有關。
北美脊髓損傷治療市場 領導者有：
- 諾華公司（瑞士）
- 輝瑞公司（美國）
- 美敦力（愛爾蘭）
- Zimmer Biomet（美國）
- 雅培（美國）
- Amneal Pharmaceuticals LLC（美國）
- 賽諾菲（法國）
- Axonis Therapeutics（美國）
- Zydus集團（印度）
- Lineage Cell Therapeutics, Inc.（美國）
- 太陽製藥工業有限公司（印度）
- Camber Pharmaceuticals, Inc.（美國）
- 雷迪博士實驗室有限公司（印度）
- Teva Pharmaceuticals US, Inc.（以色列）
- Niksan Pharmaceuticals（印度）
- Covis Pharma GmbH（瑞士）
- 印度脊髓損傷中心（印度）
- Jubilant Cadista Pharmaceuticals Inc.（美國）
- 強生公司（美國）
- Nervgen Pharma Corp（加拿大）
- Advacare Pharma（美國）
- 波士頓科學公司（美國）
- Vasudha Pharma（印度）
- Enomark（印度）
- Glenmark Pharmaceuticals US Inc.（美國）
- Inova Pharmaceuticals（澳洲）
- Globus Medical（美國）
- Zimvie Inc.（美國）
- Bioaxone（加拿大）
北美脊髓損傷治療市場最新動態
- 2023 年 5 月，雅培宣布 FDA 已批准其脊髓刺激 (SCS) 設備用於治療未接受或沒有資格接受背部手術的人群的慢性背痛，即非手術背痛。
- 2025 年 1 月，雅培公佈了新的四年數據，顯示其專有的 BurstDR 脊髓刺激 (SCS) 技術可以為慢性疼痛患者，尤其是背部和腿部疼痛提供長期持續的緩解。這些數據進一步證明了人們對該療法的高度滿意度，它代表了一項多年追蹤研究四年來的成果，並將在佛羅裡達州奧蘭多舉行的北美神經調節 (NANS) 2025 年年會上分享。
- 2024 年 8 月，Zimmer Biomet 簽署協議收購 OrthoGrid Systems，利用 OrthoGrid 的 AI 驅動髖關節 AI 手術導引平台擴展其髖關節產品組合。此次收購包括基於人工智慧的透視系統，提高了手術的準確性和效率
- 2020 年 12 月，坎伯製藥公司推出了巴氯芬片，這是 Lioresal 的仿製藥。巴氯芬用於治療多發性硬化症和脊髓損傷等引起的肌肉疼痛、痙攣和僵硬。有 10 毫克和 20 毫克兩種規格，可透過放鬆肌肉和緩解不適來緩解這些疾病患者的症狀
- 2020年12月，Globus Medical宣布已與美國領先的集團採購組織Premier簽訂了集團採購協議。該公司達成的這項協議提高了其在市場上的信譽，從而增加了未來的收入
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
5 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: REGULATIONS
5.1 ONGOING COMPLIANCE AND UPDATES:
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING COLLABORATION AND EXPANDING PARTNERSHIPS
6.1.2 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT METHODS
6.1.3 INCREASING HEALTHCARE EXPENDITURE
6.1.4 ENHANCED REHABILITATION TECHNIQUES
6.2 RESTRAINTS
6.2.1 POTENTIAL RISKS, SIDE EFFECTS, AND COMPLICATIONS OF SPINAL CORD TREATMENTS
6.2.2 REGULATORY BARRIERS LIMIT MARKET GROWTH BY DELAYING TREATMENT APPROVALS AND ACCESSIBILITY
6.3 OPPORTUNITIES
6.3.1 RISING GERIATRIC POPULATION
6.3.2 RISING INCIDENCE OF TRAUMATIC INJURIES
6.3.3 INCORPORATION OF ARTIFICIAL INTELLIGENCE AND BIG DATA ANALYTICS
6.4 CHALLENGES
6.4.1 LIMITED UNDERSTANDING RELATED TO SPINAL CORD INJURY TREATMENTS
6.4.2 HIGH COSTS ASSOCIATED WITH THE TREATMENTS
7 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE
7.1 OVERVIEW
7.2 NON-OPERATIVE MANAGEMENT
7.2.1 THERAPY
7.2.1.1 Rehabilitation Therapy
7.2.1.1.1 PHYSICAL
7.2.1.1.2 OCCUPATIONAL OR SPEECH THERAPY
7.2.1.2 INTRATHECAL BACLOFEN THERAPY (IBT)
7.2.2 MEDICATION
7.2.2.1 ANTICONVULSANTS
7.2.2.1.1 Pregabalin
7.2.2.1.2 Gabapentin
7.2.2.1.3 Others
7.2.2.2 CORTICOSTEROIDS
7.2.2.2.1 Methylprednisolone
7.2.2.2.2 Dexamethasone
7.2.2.3 ANTIDEPRESSANTS
7.2.2.3.1 SSRIs (Selective Serotonin Reuptake Inhibitors)
7.2.2.3.2 SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors)
7.2.2.3.3 Tricyclic Drugs
7.2.2.3.4 Anxiety Medications
7.2.2.4 ANTISPASMODICS AND MUSCLE RELAXANTS
7.2.2.4.1 Benzodiazepines
7.2.2.4.2 Alpha-2 Agonists
7.2.2.4.3 Other GABA Agonists
7.2.2.4.4 Others
7.2.2.5 NSAIDS
7.2.2.5.1 Ibuprofen
7.2.2.5.2 Naproxen
7.2.2.5.3 Others
7.2.2.6 NARCOTIC ANALGESICS
7.2.2.7 ANTIBIOTICS
7.2.2.7.1 β-Lactams (Penicillins, Cephalosporins)
7.2.2.7.2 Macrolides (Azithromycin, Erythromycin)
7.2.2.7.3 Minocycline (Tetracycline Type)
7.2.2.7.4 Dapsone
7.2.2.7.5 Others (Fluoroquinolones, Aminoglycosides, etc.)
7.2.2.8 Medrol
7.2.2.9 Lioresal
7.2.2.10 Lyrica
7.2.2.11 Neurontin
7.2.2.12 Zanaflex
7.2.2.13 Gralise
7.2.2.14 Rilutek
7.3 OPERATIVE MANAGEMENT
7.3.1 DECOMPRESSION SURGERY
7.3.1.1 Discectomy Or Microdiscectomy
7.3.1.2 Laminectomy
7.3.1.3 Posterior Microdiscectomy/ Microdecompression
7.3.1.4 Foraminectomy
7.3.1.5 Reconstructive Spinal Surgery
7.3.1.6 Posterior Cervical Laminectomy
7.3.1.7 Laminotomy
7.3.2 DISC REPLACEMENT
7.3.2.1 Artificial Cervical Disc Implantation
7.3.2.2 Artificial Disc Surgery/ Spinal Arthroplasty
7.3.3 DISC AND FACET JOINT REMOVAL
7.3.3.1 Anterior Cervical Discectomy
7.3.3.2 Spinal Fusion
7.3.3.2.1 Lumbar Spinal Fusion
7.3.3.2.2 Cervical Spinal Fusion
7.3.3.2.3 Sextant Fusion
7.3.3.3 Medial Facetectomy
7.3.3.3.1 REMOVE TWO FACET JOINT
7.3.3.3.2 REMOVE ONE FACET JOINT
8 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY
8.1 OVERVIEW
8.2 CERVICAL SPINAL CORD INJURIES
8.2.1 COMPLETE SPINAL CORD INJURIES
8.2.2 PARTIAL SPINAL CORD INJURIES
8.3 THORACIC SPINAL CORD INJURIES
8.3.1 COMPLETE SPINAL CORD INJURIES
8.3.2 PARTIAL SPINAL CORD INJURIES
8.4 LUMBAR SPINAL CORD INJURIES
8.4.1 COMPLETE SPINAL CORD INJURIES
8.4.2 PARTIAL SPINAL CORD INJURIES
8.5 SACRAL SPINAL CORD INJURIES
8.5.1 COMPLETE SPINAL CORD INJURIES
8.5.2 PARTIAL SPINAL CORD INJURIES
9 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE
9.1 OVERVIEW
9.2 COMPLETE SPINAL CORD INJURIES
9.3 PARTIAL SPINAL CORD INJURIES
10 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY GENDER
10.1 OVERVIEW
10.2 MALE
10.2.1 ADULT
10.2.2 GERIATIC
10.2.3 CHILDREN
10.3 FEMALE
10.3.1 ADULT
10.3.2 GERIATIC
10.3.3 CHILDREN
11 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 TRAUMA CENTERS
11.4 SPECIALTY CLINICS
11.5 CLINICS
11.6 AMBULATORY AND RESEARCH CENTERS
11.7 OTHERS
12 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: GLOBAL
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 PFIZER INC.
15.1.1 COMPANY SHARE ANALYSIS
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENT
15.2 ABBOTT
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 MEDTRONIC
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENT
15.4 NOVARTIS AG
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 ZIMMER BIOMET
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENT
15.6 AMNEAL PHARMACEUTICALS LLC
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AXONIS THERAPEUTICS
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENT
15.8 ADVACARE PHARMA
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENT
15.9 BIOAXONE BIOSCIENCES
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENT
15.1 BOSTON SCIENTIFIC CORPORATION
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 COVIS PHARMA GMBH.
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.12 CAMBER PHARMACEUTICALS, INC
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENT
15.13 DR. REDDY’S LABORATORIES LTD
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 ENOMARK PHARMA
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENT
15.15 GLENMARK PHARMACEUTICALS INC.,
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 GLOBUS MEDICAL
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENTS/NEWS
15.17 INOVA PHARMACEUTICALS
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENT
15.18 INDIAN SPINAL INJURIES CENTRE
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENT
15.19 JUBILANT CADISTA PHARMACEUTICALS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 PRODUCT PORTFOLIO
15.19.3 RECENT DEVELOPMENT
15.2 JOHNSON & JOHNSON SERVICES, INC
15.20.1 COMPANY SNAPSHOT
15.20.2 REVENUE ANALYSIS
15.20.3 PRODUCT PORTFOLIO
15.20.4 RECENT DEVELOPMENTS
15.21 LINEAGE CELL THERAPEUTICS, INC.
15.21.1 COMPANY SNAPSHOT
15.21.2 ANNUAL REVENUE
15.21.3 PRODUCT PORTFOLIO
15.21.4 RECENT DEVELOPMENT
15.22 NERVGEN PHARMA CORP.
15.22.1 COMPANY SNAPSHOT
15.22.2 REVENUE ANALYSIS
15.22.3 PRODUCT PIPELINE PORTFOLIO
15.22.4 RECENT DEVELOPMENT
15.23 NIKSAN PHARMACEUTICAL
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENT
15.24 SUN PHARMACEUTICAL INDUSTRIES LTD.
15.24.1 COMPANY SNAPSHOT
15.24.2 REVENUE ANALYSIS
15.24.3 PRODUCT PORTFOLIO
15.24.4 RECENT DEVELOPMENT
15.25 SANOFI
15.25.1 COMPANY SNAPSHOT
15.25.2 REVENUE ANALYSIS
15.25.3 PRODUCT PORTFOLIO
15.25.4 RECENT DEVELOPMENT
15.26 TEVA PHARMACEUTICALS USA, INC.
15.26.1 COMPANY SNAPSHOT
15.26.2 REVENUE ANALYSIS
15.26.3 PRODUCT PORTFOLIO
15.26.4 RECENT DEVELOPMENT
15.27 VASUDHA PHARMA
15.27.1 COMPANY SNAPSHOT
15.27.2 PRODUCT PORTFOLIO
15.27.3 RECENT DEVELOPMENT
15.28 ZIMVIE INC.
15.28.1 COMPANY SNAPSHOT
15.28.2 REVENUE ANALYSIS
15.28.3 PRODUCT PORTFOLIO
15.28.4 RECENT NEWS
15.29 ZYDUS GROUP
15.29.1 COMPANY SNAPSHOT
15.29.2 REVENUE ANALYSIS
15.29.3 PRODUCT PORTFOLIO
15.29.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 NORTH AMERICA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 NORTH AMERICA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 NORTH AMERICA THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 5 NORTH AMERICA REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 NORTH AMERICA MEDICATION IN SPINAL CORD INJURY TREATMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 7 NORTH AMERICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 NORTH AMERICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 9 NORTH AMERICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 10 NORTH AMERICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 NORTH AMERICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 12 NORTH AMERICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 13 NORTH AMERICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 NORTH AMERICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 15 NORTH AMERICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 16 NORTH AMERICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE 2018-2032 (USD THOUSAND)
TABLE 17 NORTH AMERICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 18 NORTH AMERICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 19 NORTH AMERICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 20 NORTH AMERICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 21 NORTH AMERICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 22 NORTH AMERICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 24 NORTH AMERICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 25 NORTH AMERICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 NORTH AMERICA BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 NORTH AMERICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 NORTH AMERICA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 NORTH AMERICA DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 NORTH AMERICA DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 NORTH AMERICA DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 NORTH AMERICA SPINAL FUSION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 NORTH AMERICA MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE 2018-2032 (USD THOUSAND)
TABLE 36 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 37 NORTH AMERICA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 NORTH AMERICA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA COMPLETE SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA PARTIAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA SPINAL CORD INJURY TREA TMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 54 NORTH AMERICA HOSPITALS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 NORTH AMERICA TRAUMA CENTERS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 56 NORTH AMERICA SPECIALITY CLINICS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 57 NORTH AMERICA CLINICS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 58 NORTH AMERICA AMBULATORY AND RESEARCH CENTERS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 59 NORTH AMERICA OTHERS IN SPINAL CORD INJURY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 60 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 61 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 NORTH AMERICA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 NORTH AMERICA THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 NORTH AMERICA REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 NORTH AMERICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 66 NORTH AMERICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 NORTH AMERICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 68 NORTH AMERICA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 69 NORTH AMERICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 NORTH AMERICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 71 NORTH AMERICA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 72 NORTH AMERICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 NORTH AMERICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 74 NORTH AMERICA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 75 NORTH AMERICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 NORTH AMERICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 77 NORTH AMERICA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 78 NORTH AMERICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 NORTH AMERICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 80 NORTH AMERICA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 81 NORTH AMERICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 NORTH AMERICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 83 NORTH AMERICA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 84 NORTH AMERICA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 NORTH AMERICA DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 NORTH AMERICA DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 NORTH AMERICA DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 88 NORTH AMERICA SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 89 NORTH AMERICA MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 92 NORTH AMERICA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 NORTH AMERICA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 94 NORTH AMERICA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 95 NORTH AMERICA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 NORTH AMERICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 97 NORTH AMERICA BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 NORTH AMERICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 99 NORTH AMERICA ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 101 NORTH AMERICA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 102 NORTH AMERICA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 103 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 104 NORTH AMERICA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 105 U.S. SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 U.S. NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 U.S. THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 U.S. REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 U.S. MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 U.S. ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 U.S. ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 112 U.S. ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 113 U.S. CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 U.S. CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 115 U.S. CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 116 U.S. ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 U.S. ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 118 U.S. ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 119 U.S. ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 U.S. ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 121 U.S. ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 122 U.S. NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 U.S. NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 124 U.S. NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 125 U.S. ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 U.S. ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 127 U.S. ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 128 U.S. OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 U.S. DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 U.S. DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 131 U.S. DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 U.S. SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 U.S. MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 U.S. SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 U.S. SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 136 U.S. CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 U.S. THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 U.S. LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 U.S. SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 U.S. MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 U.S. BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 U.S. MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 143 U.S. ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 U.S. SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 145 U.S. MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 146 U.S. FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 147 U.S. SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 148 U.S. MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 149 CANADA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 CANADA NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 CANADA THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 CANADA REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 CANADA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 CANADA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 CANADA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 156 CANADA ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 157 CANADA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 CANADA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 159 CANADA CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 160 CANADA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 CANADA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 162 CANADA ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 163 CANADA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 CANADA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 165 CANADA ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 166 CANADA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 CANADA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 168 CANADA NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 169 CANADA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 CANADA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 171 CANADA ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 172 CANADA OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 CANADA DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 CANADA DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 CANADA DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 CANADA SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 CANADA MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 CANADA SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 CANADA SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 180 CANADA CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 CANADA THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 CANADA LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 CANADA SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 CANADA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 CANADA BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 CANADA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 187 CANADA ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 188 CANADA SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 189 CANADA MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 190 CANADA FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 191 CANADA SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 192 CANADA MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 193 MEXICO SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 MEXICO NON-OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 MEXICO THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 MEXICO REHABILITATION THERAPY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 MEXICO MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 MEXICO ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 MEXICO ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 200 MEXICO ANTICONVULSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 201 MEXICO CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 MEXICO CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 203 MEXICO CORTICOSTEROIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 204 MEXICO ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 MEXICO ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 206 MEXICO ANTIDEPRESSANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 207 MEXICO ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 MEXICO ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 209 MEXICO ANTISPASMODICS AND MUSCLE RELAXANTS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 210 MEXICO NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 MEXICO NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 212 MEXICO NSAIDS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 213 MEXICO ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 MEXICO ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (THOUSAND UNITS)
TABLE 215 MEXICO ANTIBIOTICS IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD/UNITS)
TABLE 216 MEXICO OPERATIVE MANAGEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 MEXICO DECOMPRESSION SURGERY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 MEXICO DISC REPLACEMENT IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 MEXICO DISC AND FACET JOINT REMOVAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 MEXICO SPINAL FUSION IN ANTERIOR CERVICAL DISCECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 221 MEXICO MEDIAL FACETECTOMY IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 MEXICO SPINAL CORD INJURY TREATMENT MARKET, BY INJURY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 MEXICO SPINAL CORD INJURY TREATMENT MARKET, BY LEVEL OF INJURY, 2018-2032 (USD THOUSAND)
TABLE 224 MEXICO CERVICAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 MEXICO THORACIC SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 MEXICO LUMBAR SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 MEXICO SACRAL SPINAL CORD INJURIES IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 MEXICO MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 MEXICO BRANDED IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 MEXICO MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 231 MEXICO ORAL IN SPINAL CORD INJURY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 MEXICO SPINAL CORD INJURY TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 233 MEXICO MALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 234 MEXICO FEMALE IN SPINAL CORD INJURY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 235 MEXICO SPINAL CORD INJURY TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 236 MEXICO MEDICATION IN SPINAL CORD INJURY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
图片列表
FIGURE 1 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 TWO SEGMENTS COMPRISE THE NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET, BY TYPE
FIGURE 14 GROWING COLLABORATION AND EXPANDING PARTNERSHIPS IS EXPECTED TO DRIVE THE NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 NON-OPERATIVE MANAGEMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SPINAL CORD INJURY TREATMENT IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 16 MARKET OVERVIEW
FIGURE 17 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, 2024
FIGURE 18 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 20 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, 2024
FIGURE 22 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, 2025-2032 (USD THOUSAND)
FIGURE 23 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, CAGR (2025-2032)
FIGURE 24 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY LEVEL OF INJURY, LIFELINE CURVE
FIGURE 25 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, 2024
FIGURE 26 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 27 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, CAGR (2025-2032)
FIGURE 28 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY INJURY TYPE, LIFELINE CURVE
FIGURE 29 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, 2024
FIGURE 30 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 31 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 32 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 33 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, 2024
FIGURE 34 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 35 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 36 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 38 NORTH AMERICA SPINAL CORD INJURY TREATMENT MARKET: COMPANY SHARE 2024 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
